Opioid use disorder: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
(7 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
− | == |
+ | ==Background== |
+ | *A [[substance use disorder]] involving heroin, fentanyl, or other opioid medications |
||
− | * Risk of addiction ~= 10% for non-cancer ([https://doi.org/10.1097/01.j.pain.0000460357.01998.f1 Vowles et al in Pain]) |
||
+ | *For reference, 1 point of street fentanyl is 100 mg, which is usually 4.4 mg of pure fentanyl |
||
− | == |
+ | ===Epidemiology=== |
+ | *The risk of OUD among patients treated with opioids for chronic pain is around 8 to 30% |
||
⚫ | |||
+ | ==Management== |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
− | * Recommend Suboxone first-line |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
− | ==== Suboxone (buprenorphine/naloxone) ==== |
||
− | * |
+ | *Recommend [[Suboxone]] first-line |
⚫ | |||
− | * Buprenorphine is partial mu-opioid receptor agonist |
||
⚫ | |||
− | * Theoretical ceiling effect |
||
− | * Strong receptor affinity, displaces other opioids |
||
+ | ==Prevention== |
||
− | ===== Full Start ===== |
||
+ | *Follow safe prescribing practices |
||
− | * Precipitates withdrawal, so wait 12-24h for short-acting, 18-36h for long-acting, or after tapering methadone |
||
+ | *Risk assessment |
||
− | * Ensure COWS ≥12, then give 4mg, wait a few hours, give another 4mg |
||
+ | **Consider their personal and family history of psychiatric illness and substance use disorder |
||
− | * Day 2: 12mg; Day 3: 16mg; discharge and refer to Addictions clinic |
||
+ | **Consider their social history, including their living situation, safety of housing, personal safety, children or dependents, and social supports |
||
+ | **Can use tools such as the [[opioid risk tool]] or [[SOAPP-R]] as a more formal risk assessment |
||
+ | **Physical exam, looking for signs of substance use and its complications |
||
+ | **Bloodwork, including liver function tests, hemoglobin, and MCV |
||
− | == |
+ | ==Further Reading== |
+ | *Management of opioid use disorders: a national clinical practice guideline. ''CMAJ''. 2018;190(9):e247-e257. doi: [https://doi.org/10.1503/cmaj.170958 10.1503/cmaj.170958] |
||
− | * Recommended as second-line by Canadian guidelines |
||
+ | *Opioid Agonist Therapy:A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. 2021. Available at: https://www.camh.ca/-/media/files/professionals/canadian-opioid-use-disorder-guideline2021-pdf.pdf |
||
⚫ | |||
− | == Further Reading == |
||
− | |||
− | * [http://www.cmaj.ca/content/190/9/E247 Canadian Guidelines] |
||
− | |||
⚫ |
Latest revision as of 14:59, 24 October 2021
Background
- A substance use disorder involving heroin, fentanyl, or other opioid medications
- For reference, 1 point of street fentanyl is 100 mg, which is usually 4.4 mg of pure fentanyl
Epidemiology
- The risk of OUD among patients treated with opioids for chronic pain is around 8 to 30%
Management
- Precipitated withdrawal more dangerous than natural withdrawal
Acute Overdose
- First give boluses of naloxone 0.04mg to 0.08mg IV to improve respiratory depression escalated quickly q2-3 minutes up to 0.4, 2, 4, 10, 15mg (start low and go fast)
- Then start infusion of 2/3 the effective dose per hour
- QRS and QT lengthening by blocking Na and K channels
- May need repeated defibrillation, overdrive pacing, or ECMO
Opioid Substitution Therapy (OST)
Prevention
- Follow safe prescribing practices
- Risk assessment
- Consider their personal and family history of psychiatric illness and substance use disorder
- Consider their social history, including their living situation, safety of housing, personal safety, children or dependents, and social supports
- Can use tools such as the opioid risk tool or SOAPP-R as a more formal risk assessment
- Physical exam, looking for signs of substance use and its complications
- Bloodwork, including liver function tests, hemoglobin, and MCV
Further Reading
- Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):e247-e257. doi: 10.1503/cmaj.170958
- Opioid Agonist Therapy:A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. 2021. Available at: https://www.camh.ca/-/media/files/professionals/canadian-opioid-use-disorder-guideline2021-pdf.pdf